Literature DB >> 33584195

Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort.

Jan O Aasly1,2.   

Abstract

The first families with LRRK2 related Parkinson's disease (PD) were presented around 15 years ago and numerous papers have described the characteristics of the LRRK2 phenotype. The prevalence of autosomal dominant PD varies around the world mainly depending on local founder effects. The highest prevalence of LRRK2 G2019S PD in Norway is located to the central part of the country and most families could be traced back to common ancestors. The typical Norwegian LRRK2 phenotype is not different from classical PD and similar to that seen in most other LRRK2 families. The discovery of LRRK2 PD has allowed us to follow-up multi-incident families and to study their phenotype longitudinally. In the Norwegian LRRK2 families there has been a significantly higher incidence of inflammatory diseases like multiple sclerosis and rheumatoid arthritis that seen in other PD populations. Recent studies in LRRK2 mechanisms have indicated that this protein may be crucial in initiating disease processes. In this short survey of 100 Norwegian mutation carriers followed through more than 15 years are presented. The prevalence of inflammatory diseases among these cases is highlighted. The role of LRRK2 in the conversion process from carrier status to PD phenotype is still unknown and disease generating mechanisms important for initiating LRRK2 PD are still to be identified.
Copyright © 2021 Aasly.

Entities:  

Keywords:  LRRK2; Parkinson’s disease; achalasia; dementia; inflammation; multiple sclerosis; rheumatoid arthritis

Year:  2021        PMID: 33584195      PMCID: PMC7876287          DOI: 10.3389/fnins.2021.634666

Source DB:  PubMed          Journal:  Front Neurosci        ISSN: 1662-453X            Impact factor:   4.677


  66 in total

1.  Multiple sclerosis and risk of Parkinson's disease: a Danish nationwide cohort study.

Authors:  N M Nielsen; B Pasternak; E Stenager; N Koch-Henriksen; M Frisch
Journal:  Eur J Neurol       Date:  2013-09-19       Impact factor: 6.089

2.  Use of ibuprofen and risk of Parkinson disease.

Authors:  Xiang Gao; Honglei Chen; Michael A Schwarzschild; Alberto Ascherio
Journal:  Neurology       Date:  2011-03-02       Impact factor: 9.910

3.  Achalasia: incidence, prevalence and survival. A population-based study.

Authors:  D C Sadowski; F Ackah; B Jiang; L W Svenson
Journal:  Neurogastroenterol Motil       Date:  2010-05-11       Impact factor: 3.598

4.  Subthalamic nucleus stimulation is efficacious in patients with Parkinsonism and LRRK2 mutations.

Authors:  Michael Schüpbach; Ebba Lohmann; Mathieu Anheim; Suzanne Lesage; Virginie Czernecki; Sadek Yaici; Yulia Worbe; Perrine Charles; Marie-Laure Welter; Pierre Pollak; Alexandra Dürr; Yves Agid; Alexis Brice
Journal:  Mov Disord       Date:  2007-01       Impact factor: 10.338

5.  Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers.

Authors:  J O Aasly; M Shi; V Sossi; T Stewart; K K Johansen; Z K Wszolek; R J Uitti; K Hasegawa; T Yokoyama; C P Zabetian; H M Kim; J B Leverenz; C Ginghina; J Armaly; K L Edwards; K W Snapinn; A J Stoessl; J Zhang
Journal:  Neurology       Date:  2011-12-14       Impact factor: 9.910

6.  Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.

Authors:  Maria Sierra; Pascual Sánchez-Juan; María Isabel Martínez-Rodríguez; Isabel González-Aramburu; Inés García-Gorostiaga; María Remedios Quirce; Enrique Palacio; José Manuel Carril; José Berciano; Onofre Combarros; Jon Infante
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

7.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology.

Authors:  Z K Wszolek; R F Pfeiffer; Y Tsuboi; R J Uitti; R D McComb; A J Stoessl; A J Strongosky; A Zimprich; B Müller-Myhsok; M J Farrer; T Gasser; D B Calne; D W Dickson
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

8.  Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism.

Authors:  Vincenzo Bonifati; Patrizia Rizzu; Marijke J van Baren; Onno Schaap; Guido J Breedveld; Elmar Krieger; Marieke C J Dekker; Ferdinando Squitieri; Pablo Ibanez; Marijke Joosse; Jeroen W van Dongen; Nicola Vanacore; John C van Swieten; Alexis Brice; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink
Journal:  Science       Date:  2002-11-21       Impact factor: 47.728

9.  The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.

Authors:  Shu-Ying Liu; Daryl J Wile; Jessie Fanglu Fu; Jason Valerio; Elham Shahinfard; Siobhan McCormick; Rostom Mabrouk; Nasim Vafai; Jess McKenzie; Nicole Neilson; Alexandra Perez-Soriano; Julieta E Arena; Mariya Cherkasova; Piu Chan; Jing Zhang; Cyrus P Zabetian; Jan O Aasly; Zbigniew K Wszolek; Martin J McKeown; Michael J Adam; Thomas J Ruth; Michael Schulzer; Vesna Sossi; A Jon Stoessl
Journal:  Lancet Neurol       Date:  2018-02-16       Impact factor: 44.182

10.  Antineuronal antibodies in idiopathic achalasia and gastro-oesophageal reflux disease.

Authors:  P L Moses; L M Ellis; M R Anees; W Ho; R I Rothstein; J B Meddings; K A Sharkey; G M Mawe
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.